Literature DB >> 18562449

Viral infections in paediatric patients receiving conventional cancer chemotherapy.

A Simon1, O Schildgen, F Schuster.   

Abstract

In severely immunocompromised patients, the diagnosis of viral infections relies on PCR/RT-PCR based methods. The availability of these modern diagnostic tools facilitates timely diagnosis and contributes to our increasing knowledge of the epidemiology and clinical spectrum of common and emerging viral pathogens in this highly susceptible population. Viral infections may result in life threatening disease in paediatric cancer patients after stem cell transplantation and also during conventional chemotherapy. Often, clinical symptoms are a consequence of endogenous reactivation of latent viral infection. Many of these viruses are easily transmitted between patients, relatives and health care workers. As prolonged symptomatic and asymptomatic viral shedding is a common feature in paediatric cancer patients, it is necessary to implement strategies for the prevention and control of these communicable pathogens in the hospital setting and in the outpatient clinic. Although no randomised controlled studies on paediatric cancer patients are available, physicians should be aware of potential treatment options since early treatment may prevent a complicated or fatal outcome and shorten the period of contagiosity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562449     DOI: 10.1136/adc.2007.132225

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  2 in total

Review 1.  Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation.

Authors:  Brian T Fisher; Sarah Alexander; Christopher C Dvorak; Theoklis E Zaoutis; Danielle M Zerr; Lillian Sung
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

2.  Impact of influenza-like illness and effectiveness of influenza vaccination in oncohematological children who have completed cancer therapy.

Authors:  Susanna Esposito; Valerio Cecinati; Barbara Scicchitano; Giovanni Carlo Delvecchio; Nicola Santoro; Doriana Amato; Claudio Pelucchi; Momcilo Jankovic; Domenico De Mattia; Nicola Principi
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.